This meta-analysis investigated the effectiveness of orthokeratology in controlling the progression of anisomyopia (unilateral myopia or bilateral anisomyopia) in Chinese children. Total anisomyopia decreased at 2-year follow up, indicating orthokeratology may be a safe clinical method to slow myopia progression coupled with reducing interocular axial length difference.
Do you check your patient’s binocular vision function after cycloplegic refraction? Is this useful? An unexpected finding in this case leads to discussion of binocular vision changes in cycloplegic conditions, ideal management for exophores, and even the impact of low-dose atropine.
How can we identify pseudomyopia? The IMI defines myopia as -0.50D or more when accommodation is relaxed. Yet recent data indicates that a quarter of 6-year-olds may present as myopic when they’re in fact exhibiting pseudomyopia. Explore more on this topic and how to relax accommodation for accurate refractions in children.
Most atropine currently prescribed for myopia control is compounded rather than being commercially mass manufactured. How could this influence research results and clinical outcomes? Learn more about compounded topical atropine including questions to ask your compounding pharmacist.
How consistent is compounded topical atropine from bottle-to-bottle? What clinical results could indicate variability? Read more in this clinical case where a miniscule change in concentration gave notably better clinical outcomes.
Is a 3-year-old too young for low-dose atropine treatment? What about if they’re a pre-myope? Learn more about balancing proactive management with the research evidence and clinical considerations.
Atropine is a treatment for myopia control, but do combination treatments such as with orthokeratology increase the efficacy? Learn about how well it works, which concentration, for whom it works best, side effects, treatment duration and more.
低浓度的阿托品for Myopia Progression (LAMP) Study has provided invaluable data on comparisons between 0.05%, 0.025% and 0.01% atropine treatment. The three year data has shown 0.05% to be most effective for continued treatment, while children discontinued showed a small, ‘clinically insignificant’ rebound effect. Learn more about the one, two and three year LAMP data here.
The long-term safety of contact lens wear in children is a known concern amongst parents and eye care practitioners alike. This six year study demonstrated successful contact lens wear in a group of 8-12 year olds, with no serious contact lens adverse events reported and no change in clinical ocular signs compared to pre-contact lens wear. This demonstrates that children as young as 8 can successfully wear daily disposable contact lenses for multiple consecutive years.
In 2021, the World Council of Optometry (WCO) passed a resolution that publicly declares support for myopia management as standard of care. Since then, CooperVision has supported the WCO to empower eye care professionals to put this into action, with a multilingual online resource launched and more being added throughout 2022. Explore and learn more here.
